Form 4: Aclaris Therapeutics CFO Kevin Balthaser Reports Stock Transactions

Aclaris Therapeutics' Chief Financial Officer, Kevin Balthaser, reported multiple transactions involving the acquisition and disposal of company stock and restricted stock units.

Summary

• Kevin Balthaser, the Chief Financial Officer of Aclaris Therapeutics, has reported several transactions involving the company's stock.
• These transactions include the acquisition of common stock through the vesting of restricted stock units and the disposal of shares to cover tax obligations.
• On December 31, 2024, Mr. Balthaser acquired 73,750 shares through restricted stock unit vesting and disposed of 30,732 shares at $2.48 per share for tax purposes.
• On January 1, 2025, he acquired 7,500 shares through restricted stock unit vesting and disposed of 2,430 shares at $2.48 per share for tax purposes.
• On January 2, 2025, he acquired 13,200 shares through restricted stock unit vesting and disposed of 5,059 shares at $2.48 per share for tax purposes.
• Additionally, Mr. Balthaser was granted 40,000 restricted stock units on January 2, 2025.
• The reported transactions resulted in Mr. Balthaser holding 80,926 shares of common stock and 26,800 restricted stock units as of January 2, 2025.

Sentiment

Score: 6

Explanation: The document reflects routine transactions related to executive compensation. There is no indication of positive or negative sentiment, it is a neutral disclosure.

Positives

• The vesting of restricted stock units indicates that Mr. Balthaser is meeting the conditions of his employment agreement.
• The acquisition of shares through vesting increases his stake in the company.

Negatives

• The disposal of shares to cover tax obligations reduces Mr. Balthaser's direct holdings in the company.

Risks

• The sale of shares by an executive could be perceived negatively by the market, although these sales are for tax obligations related to vesting.
• Future vesting events could lead to further sales of shares to cover tax obligations.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice in publicly traded companies. It provides transparency into the executive's holdings and transactions.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for publicly traded companies in the United States.
• The transactions reported are typical for executives who receive stock-based compensation.
• The vesting schedules and tax withholding practices are consistent with industry norms.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
• The transactions do not have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Kevin Balthaser, CFO, stock transactions, restricted stock units, insider trading, SEC Form 4, vesting, tax obligations